JY
ZVRA icon

Jeff Yass’s Zevra Therapeutics ZVRA Stock Holding History

Jeff Yass’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Sell
157,100
-295,700
-65% -$3.29M ﹤0.01% 6216
2026
Q1 		$4.22M Buy
452,800
+255,600
+130% +$2.3M ﹤0.01% 4564
2025
Q4 		$1.77M Buy
197,200
+23,900
+14% +$226K ﹤0.01% 5908
2025
Q3 		$1.65M Buy
173,300
+28,800
+20% +$289K ﹤0.01% 6196
2025
Q2 		$1.27M Buy
144,500
+91,600
+173% +$743K ﹤0.01% 6822
2025
Q1 		$396K Sell
52,900
-39,300
-43% -$312K ﹤0.01% 9417
2024
Q4 		$769K Buy
92,200
+24,500
+36% +$209K ﹤0.01% 7606
2024
Q3 		$470K Buy
67,700
+55,600
+460% +$377K ﹤0.01% 8602
2024
Q2 		$59.3K Sell
12,100
-27,200
-69% -$129K ﹤0.01% 11334
2024
Q1 		$228K Buy
39,300
+20,700
+111% +$127K ﹤0.01% 10322
2023
Q4 		$122K Sell
18,600
-28,200
-60% -$132K ﹤0.01% 11166
2023
Q3 		$226K Sell
46,800
-108,400
-70% -$541K ﹤0.01% 9970
2023
Q2 		$792K Buy
155,200
+53,800
+53% +$290K ﹤0.01% 7220
2023
Q1 		$558K Sell
101,400
-46,800
-32% -$248K ﹤0.01% 8297
2022
Q4 		$680K Sell
148,200
-65,800
-31% -$334K ﹤0.01% 7096
2022
Q3 		$1.33M Buy
214,000
+19,400
+10% +$110K ﹤0.01% 5883
2022
Q2 		$868K Sell
194,600
-105,100
-35% -$479K ﹤0.01% 6881
2022
Q1 		$1.51M Sell
299,700
-627,300
-68% -$3.99M ﹤0.01% 6133
2021
Q4 		$8.07M Buy
927,000
+589,100
+174% +$5.26M ﹤0.01% 3009
2021
Q3 		$3.15M Buy
337,900
+89,700
+36% +$904K ﹤0.01% 4851
2021
Q2 		$3.18M Sell
248,200
-45,900
-16% -$493K ﹤0.01% 4891
2021
Q1 		$2.71M Buy
+294,100
New +$2.57M ﹤0.01% 5195
2019
Q4 		– Sell
-1,156
Closed -$13K – 10806
2019
Q3 		$13K Buy
1,156
+487
+73% +$8.8K ﹤0.01% 9993
2019
Q2 		$19K Buy
669
+44
+7% +$1.11K ﹤0.01% 10010
2019
Q1 		$17K Buy
+625
New +$23K ﹤0.01% 8611

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jeff Yass's ZVRA Position: Q2 2026 in Review

Jeff Yass increased its Zevra Therapeutics (ZVRA) stake by 66% in Q2 2026, buying an estimated $1.37M and bringing the position to 309,979 shares worth $4.45M. The position accounts for ﹤0.01% of the portfolio, ranked #4857.

Jeff Yass first reported a position in ZVRA in Q4 2015 and has held it in 33 quarters since. The position peaked at $11.5M in Q3 2025. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Jeff Yass held 309,979 shares of Zevra Therapeutics worth $4.45M as of Q2 2026.
  • Jeff Yass bought 123,397 Zevra Therapeutics shares in Q2 2026, an estimated $1.37M.
  • Zevra Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4857 holding.
  • Jeff Yass first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 33 quarters since.
  • Jeff Yass's Zevra Therapeutics position peaked at $11.5M in Q3 2025.
  • 156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.